# Cellbox Solutions

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellbox-solutions

- Industry: Medical Devices & Equipment
- Headquarters: Cologne, Germany
- Website: www.cellbox-solutions.com
- Total disclosed funding: $9.7M
- Latest round: Series A (Oct 20, 2026)
- Investors on record: 8

## About

Cellbox Solutions GmbH, located in Cologne, Germany, specializes in innovative logistics solutions for live cell transportation, ensuring optimal conditions for the integrity of sensitive biological materials during transit.Cellbox Solutions GmbH focuses on advanced live cell transport logistics, established in 2017 in Cologne, Germany. The company was founded by Kathrin Adlkofer. In March Cellbox Solutions GmbH raised EUR 3.5 million in a series A funding led by Companisto, with participation from NRW Bank. Cellbox Solutions specializes in advanced live cell transport logistics, primarily through its innovative portable CO2 incubators designed for the safe transportation of live cell cultures and tissues. The core product offerings, namely the Cellbox™ Go and Cellbox™ Shipper, cater to both short and long-distance transport needs, ensuring optimal temperature and CO2 saturation for cell viability during transit. These incubators are equipped with features such as active temperature control, active CO2 control, a rechargeable battery, and data logging capabilities, providing a comprehensive solution for maintaining the integrity of sensitive biological materials. Customers primarily include healthcare companies, biotech firms, and research institutions that require reliable logistics for transporting complex cell-based materials. The geographical markets served encompass North America, Europe, and Asia, addressing a growing demand for effective live cell shipping across these regions.Cellbox Solutions operates on a business-to-business model, generating revenue through direct sales of its flagship products, the Cellbox™ Go and Cellbox™ Shipper, as well as offering associated logistical services. Transactions typically involve clients purchasing the incubators and engaging in shipment services, which are structured to meet specific client needs related to temperature- and CO2-controlled logistics. The pricing structure reflects the high-value nature of these products, positioned within the premium segment of the market due to their specialized functionality. The company also focuses on maintaining long-term partnerships with its clients, providing ongoing support and potentially subscription-based services for fleet management solutions to ensure optimal operation of the transport devices. This transactional framework emphasizes the commitment to reliability and enhanced cell viability for critical applications in biobanking, research, and clinical settings. The company will use the March 2025 funding to support expansion international production and sales activities and to unlock new application areas, particularly in cell and gene therapy and in vitro fertilization. The company is actively designing upcoming products to enhance its offerings and plans to expand into new markets across Europe and Asia by 2026.

## Funding rounds

- Series A, Oct 20, 2026, $5.6M — Companisto, Baltic Business Angels Invest GmbH, Fraunhofer Venture, NRW.BANK
- Series A, Dec 9, 2025, $4.1M — NRW Bank, Fraunhofer Venture, Cold Chain Technologies, LLC, Companisto, CK Ventures GmbH, CaVeBel GmbH

## Investors

- NRW Bank — Series A
- Fraunhofer Venture (https://capitalatlas.ai/funds/fraunhofer-venture) — Series A
- Cold Chain Technologies, LLC — Series A
- Companisto — Series A
- CK Ventures GmbH — Series A
- CaVeBel GmbH — Series A
- Baltic Business Angels Invest GmbH — Series A
- NRW.BANK — Series A